Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH
Authors:
- 10 April 2012
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 40 (3) , 618-629
Abstract
Like cancer, pulmonary arterial hypertension (PAH) is characterised by a pro-proliferative and anti-apoptotic phenotype. In PAH, pulmonary artery smooth muscle cell (PASMC) proliferation is enhanced and apoptosis suppressed. The sustainability of this phenotype requires the activation of pro-survival transcription factors, such as signal transducer and activator of transcription (STAT)3 and nuclear factor of activated T-cells (NFAT). There are no drugs currently available that are able to efficiently and safely inhibit this axis. We hypothesised that plumbagin (PLB), a natural organic compound known to block STAT3 in cancer cells, would reverse experimental pulmonary hypertension.Using human PAH-PASMC, we demonstratedin vitrothat PLB inhibits the activation of the STAT3/NFAT axis, increasing the voltage-gated K+current bone morphogenetic protein receptor type II (BMPR2), and decreasing intracellular Ca2+contentration ([Ca2+]i), rho-associated coiled-coil containing protein kinase (ROCK)1 and interleukin (IL)-6, contributing to the inhibition of PAH-PASMC proliferation and resistance to apoptosis (proliferating cell nuclear antigen (PCNA), TUNEL, Ki67 and anexine V).In vivo, PLB oral administration decreases distal pulmonary artery remodelling, mean pulmonary artery pressure and right ventricular hypertrophy without affecting systemic circulation in both monocrotaline- and sugen/chronic hypoxia-induced PAH in rats.This study demonstrates that the STAT3/NFAT axis can be therapeutically targeted by PLB in human PAH-PASMC and experimental PAH rat models. Thus, PLB could be considered a specific and attractive future therapeutic strategy for PAH.Keywords
This publication has 57 references indexed in Scilit:
- STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH+/CD133+ stem cell-like human colon cancer cellsBiochemical and Biophysical Research Communications, 2011
- Progressive Right Ventricular Dysfunction in Patients With Pulmonary Arterial Hypertension Responding to TherapyJACC, 2011
- Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertensionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Signal Transducers and Activators of Transcription-3/Pim1 Axis Plays a Critical Role in the Pathogenesis of Human Pulmonary Arterial HypertensionCirculation, 2011
- Role for miR-204 in human pulmonary arterial hypertensionJournal of Experimental Medicine, 2011
- Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertensionJournal Of Hypertension, 2010
- Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3–microRNA Cluster 17/92 PathwayCirculation Research, 2009
- A Mitochondria-K+ Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer GrowthCancer Cell, 2007
- Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertensionJournal of Clinical Investigation, 2005
- Nitric oxide induces apoptosis by activating K+channels in pulmonary vascular smooth muscle cellsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2002